Akira Kazama

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 12

Top Topics

Induced Apoptosis

Histone Deacetylase

Renal Cell Carcinoma

Top Venues

Current oncology (Toronto, Ont.)

Journal of personalized medicine

BJU international

Prostate cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Tsutomu Anraku, Masaki Murata, Hiroo Kuroki, Akira Kazama, Yuko Shirono, Masayuki Tasaki, Vladimir Bilim, Yoshihiko Tomita
Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma. Journal of personalized medicine 14 (7) (2024)
Akira Kazama, Worapat Attawettayanon, Carlos Munoz-Lopez, Nityam Rathi, Kieran Lewis, Eran Maina, Rebecca A Campbell, Zaeem Lone, Melissa Boumitri, Jihad Kaouk, Georges-Pascal Haber, Samuel Haywood, Nima Almassi, Christopher Weight, Jianbo Li, Steven C Campbell
Parenchymal volume preservation during partial nephrectomy: improved methodology to assess impact and predictive factors. BJU international 134 (2) (2024)
Tsutomu Anraku, Masaki Murata, Hiroo Kuroki, Akira Kazama, Yuko Shirono, Masayuki Tasaki, Vladimir Bilim, Yoshihiko Tomita
Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma. Journal of personalized medicine 14 (7) (2024)
Akira Kazama, Worapat Attawettayanon, Carlos Munoz-Lopez, Nityam Rathi, Kieran Lewis, Eran Maina, Rebecca A Campbell, Zaeem Lone, Melissa Boumitri, Jihad Kaouk, Georges-Pascal Haber, Samuel Haywood, Nima Almassi, Christopher Weight, Jianbo Li, Steven C Campbell
Parenchymal volume preservation during partial nephrectomy: improved methodology to assess impact and predictive factors. BJU international (2024)
Tsutomu Anraku, Masaki Murata, Hiroo Kuroki, Akira Kazama, Yuko Shirono, Masayuki Tasaki, Vladimir Bilim, Yoshihiko Tomita
Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma. Journal of personalized medicine 14 (7) (2024)
Masaki Murata, Vladimir Bilim, Yuko Shirono, Akira Kazama, Kaede Hiruma, Masayuki Tasaki, Yoshihiko Tomita
MicroRNAs as Potential Regulators of GSK-3β in Renal Cell Carcinoma. Current issues in molecular biology 45 (9) (2023)
Yuko Shirono, Vladimir Bilim, Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita
Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells. Current oncology (Toronto, Ont.) 30 (6) (2023)
Yuko Shirono, Vladimir Bilim, Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita
Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells. Current oncology (Toronto, Ont.) 30 (6) (2023)
Yuko Shirono, Vladimir Bilim, Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita
Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells. Current oncology (Toronto, Ont.) 30 (6) (2023)
Yuko Shirono, Vladimir Bilim, Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita
Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells. Current oncology (Toronto, Ont.) 30 (6) (2023)
Akira Kazama, Toshihiro Saito, Keisuke Takeda, Kazuhiro Kobayashi, Toshiki Tanikawa, Ayae Kanemoto, Fumio Ayukawa, Yasuo Matsumoto, Tadashi Sugita, Noboru Hara, Yoshihiko Tomita
Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate cancer 2019 (2019)
Akira Kazama, Akiyoshi Katagiri, Shoko Ishikawa, Takaki Mizusawa
Continuous remission of renal cell carcinoma with tumour thrombus after severe adverse events following short-term treatment with sunitinib. BMJ case reports 2017 (2017)